The state of North Carolina currently has 55 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
Recruiting
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham... Read More
Gender:
All
Ages:
Between 21 years and 70 years
Trial Updated:
02/02/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Type 2 Diabetes
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Recruiting
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Carolina Clinical Research & Consulting at Triad Internal Medicine, Asheboro, North Carolina +4 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Recruiting
This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
02/01/2024
Locations: Coastal Children''s Services ( Site 2202), Wilmington, North Carolina
Conditions: Type 2 Diabetes Mellitus
The HARMONY Study: A Intervention to Reduce Cardiometabolic Risk in African American Women
Recruiting
This study will test whether a culturally-tailored nutrition and exercise intervention designed for African-American women will lead to sustained improvements in exercise and healthy eating through improvements in self-management mediators: mindfulness, stress management, positive reappraisal, self-regulation, and self-efficacy.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Heart Diseases, Stroke, Pre-diabetes, Hypertension, Obesity, Overweight, Stress
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Recruiting
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Accellacare - Winston-Salem, Winston-Salem, North Carolina
Conditions: Type 2 Diabetes
Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease
Recruiting
This study will be a prospective randomized implementation trial for patients hospitalized with heart failure, chronic kidney disease, and/or type 2 diabetes mellitus within Duke University Medical Center. The primary hypothesis is that a virtual quality improvement-based consult intervention will improve the rate of in-hospital evidence-based cardio-renal-metabolic medication use, particularly SGLT2 inhibitor therapy. Approximately 200 patients meeting eligibility criteria will be included in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Recruiting
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/03/2024
Locations: Site 181, Chapel Hill, North Carolina
Conditions: Hypercortisolism, Diabetes Mellitus, Type 2
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Recruiting
The objective of this clinical trial is to assess whether ladarixin treatment is effective in preserving beta-cell function and delaying the progression of type 1 diabetes (T1D) in adolescent and adult patients. The safety of ladarixin in the specific clinical setting will be also evaluated.
Gender:
All
Ages:
Between 14 years and 45 years
Trial Updated:
12/21/2023
Locations: "WakeMed Physician Practices - Pediatric Endocrinology - WakeMed Raleigh Medical Park Location", Raleigh, North Carolina
Conditions: New-onset type1 Diabetes
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
12/19/2023
Locations: UNC Chapel Hill, Chapel Hill, North Carolina
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of CT-868 in Type 1 Diabetes Mellitus
Recruiting
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose leve... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: Carmot Therapeutics Investigational Site 111, Asheville, North Carolina +2 locations
Conditions: Overweight, Obese, Type 1 Diabetes Mellitus
Postpartum Glycemia in Women at Risk For Persistent Hyperglycemia
Recruiting
GDM is characterized by decreased insulin sensitivity, decreased insulin secretion, or a combination of both. Women with GDM are at significant risk for overt T2DM later in life, and postpartum insulin sensitivity and secretion in women with GDM has not been quantified, limiting our ability to optimize screening for overt T2DM. In addition, compliance with currently recommended postpartum T2DM screening by OGTT is poor. Quantification of postpartum insulin sensitivity and secretion in women at h... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
12/16/2023
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Gestational Diabetes
Effect of Corticosteroid Injections on Blood Glucose
Recruiting
The purpose of this study is to measure the effect of various corticosteroids administered to the shoulder, knee and hip joints in diabetic patients on resultant blood glucose readings.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
12/15/2023
Locations: Duke Sports Science Institute, Durham, North Carolina
Conditions: Diabetes Mellitus, Steroid Diabetes, Shoulder Pain